Symbio’s revenue was flat, but every profit metric was down, and $7.2m was invested in mysterious “other financial assets.”

I use watchlists with target desired buy prices to help me take advantage of market volatility in a calm and measured way.

Symbio is setting itself up for acquisitive growth in Asia, but the stock is arguably priced for perfection.

Even though growth stocks are down considerably, in my view the top quality growth stocks are still up pretty overvalued.